MPharma launches an AI assistant to cut costs for SMEs
What the move actually costs — and the plays a founder can borrow.
MPharma launches an AI assistant to cut costs for SMEs
- The real cost behind the growth round.
- Why it matters now for founders — and who it affects first.
- How Zambia's market shapes the outcome.
What the move actually costs — and the plays a founder can borrow.
- The real cost behind the growth round.
- Why it matters now for founders — and who it affects first.
- How Zambia's market shapes the outcome.
For anyone building in technology, the useful question is where this changes your costs, distribution or competition — and how soon you act on it.
AI-generated summary. It can miss nuance — read the full story above for the complete picture.
In Kampala, the story of mPharma is becoming a case study in what it takes to scale across East Africa.
The team's bet is simple: scale across East Africa without burning the runway that Partech Africa just extended.
Why it matters
The founders who win here treat discipline as a feature, not a phase.
The move reframes hiring for anyone building in Zambia: get the fundamentals right before you scale.
Competitors won't sit still. Expect telco wallets to respond within the quarter.
What to watch next
- Whether mPharma can hold margins while it chases 80% retention.
- Whether the growth round buys enough runway to reach the next milestone.
- Which rivals move first, and how telco wallets counter.
Founders watching from Kampala should take notes: this is how you scale across East Africa.
